Background: One-fifth of primary care attendees suffer chronic noncancer pain, with musculoskeletal conditions the leading cause. Twelve percent of patients with chronic noncancer pain are prescribed strong opioids. Evidence suggests long-term opioid use is related to hypogonadism in men, but the relationship in women is unclear. Our aim was to investigate reproductive dysfunction in women prescribed long-term opioids for musculoskeletal pain. Methods: We undertook a matched (matched 1:1; for year of birth, year of start of follow-up and practice) cohort study of women aged 18-55 years old, with musculoskeletal pain and an opioid prescription in the Clinical Practice Research Datalink (a primary care database) between 2002 and 2013. Long-term opioid users (≥90 days) were compared with short-term opioid users (<90 days) for four reproductive conditions (abnormal menstruation, low libido, infertility and menopause) using Cox proportional hazards models. Results: A total of 44,260 women were included; the median cohort age at baseline was 43 years (Interquartile Range 36-49). Long-term opioid use was associated with an increased risk of altered menstruation (hazard ratio 1.13 95% CI 1.05-1.21) and with an increased risk of menopause (hazard ratio 1.16 95% CI 1.10-1.23). No significant association was found for libido (hazard ratio 1.19 95% CI 0.96-1.48) or infertility (hazard ratio 0.82 95% CI 0.64-1.06). Conclusions: The risk of menopause and abnormal menstruation was increased in long-term opioid users. This has implications for clinicians as reproductive dysfunction will need to be considered when prescribing long-term opioids to women with musculoskeletal conditions. Significance: This is a large-scale cohort examining the relationship between long-term opioid use and reproductive dysfunction using a UK national primary care database. There is an increased risk of reproductive dysfunction associated with long-term opioid use.
Introduction
Chronic noncancer pain (CNCP) can be defined as any painful condition lasting for 3 months or more and not associated with neoplastic disease (cancer) (Chapman et al., 2010) . Musculoskeletal (MSK) conditions are the leading cause of CNCP (Breivik et al., 2006) . Over a fifth (22%) of patients attending primary care report CNCP, women are more commonly affected than men (Gureje et al., 1998) .
Opioid prescribing has been increasing over the past 20 years and guidelines recommend their use as a second-line treatment in MSK pain (World Health Organisation, 1990; Cheung et al., 2014 ; National Institute for Health and Care Excellence, 2014) . A cross-sectional study in Europe found 12% of those with CNCP in the UK used strong opioids and 50% used weak opioids (Breivik et al., 2006) . A recent British cohort study found that the number of people starting a long-term opioid increased by 38% between 2002 and 2009 (Bedson et al., 2016) . Evidence for opioids' effectiveness in CNCP is weak (Eriksen et al., 2006; Noble et al., 2010; Higgins and Green, 2011; Kissin, 2013; Els et al., 2017a) , and there is a growing body of evidence that they can have significant side effects, including increased morbidity, mortality and overdose risk (Saunders et al., 2009; Dunn et al., 2010; Els et al., 2017b) .
Recently, concerns surrounding opioids and their effects on the endocrine system have arisen. The British Pain Society highlights the likelihood of endocrine side effects from opioids (including reproductive dysfunction), but they conclude that there still remains insufficient data to be able to quantify the risk, and a recent Cochrane review found no current evidence for hypogonadism or sexual dysfunction (The British Pain Society, 2010; Els et al., 2017b) . Current literature suggests that longterm opioid therapy has an impact on the male reproductive system, for which the primary mechanism is thought to be through suppression of the hypothalamic-pituitary-gonadal (HPG) axis which leads to low testosterone levels and reproductive and sexual dysfunction (Abs et al., 2000; Daniell, 2002; Benyamin et al., 2008; Aloisi et al., 2009; Katz and Mazer, 2009; Smith and Elliott, 2012) . Potentially, opioids may have similar biochemical and clinical effects in women, with the addition of altered menstrual cycles and possibly galactorrhoea (Ballantyne and Mao, 2003; Schmittner et al., 2005; Brown and Zueldorff, 2007; Colameco and Coren, 2009; Katz and Mazer, 2009; The British Pain Society, 2010; Brennan, 2013) . A systematic review examining reproductive dysfunction and prescribed long-term opioids in women found 12 relevant papers, and although they were small studies, the majority suggested a link between long-term opioid use and reproductive dysfunction, both biochemically (decreased sex hormones) and clinically (decreased libido and altered menstrual cycle) (Wersocki et al., 2017) .
The aim of this study was to assess if long-term opioid use for MSK pain compared with short-term use is associated with reproductive dysfunction in women.
Methods

Study setting and population
This study used data from the Clinical Practice Research Datalink (CPRD). CPRD is a high-quality, anonymized, large UK primary care database containing information on over 11 million patients from over 600 primary care practices; there are currently between 4 and 5 million active patients (Williams et al., 2012; Herrett et al., 2015) . UK primary care databases provide almost complete population coverage, as over 98% of the population are registered with general practitioners (GPs), who are the gatekeepers to secondary care (Garcia Rodriguez and Perez Gutthann, 1997; Williams et al., 2012; Herrett et al., 2015) . CPRD has been compared with the UK census and was shown to be broadly representative of the UK population in terms of age, ethnicity and sex (Herrett et al., 2010) . CPRD includes data on patients' clinical conditions and prescribed medications. For the purpose of analysis, the practices included (n = 350, all from English regions) were those linked to the Office for National Statistics (ONS) neighbourhood deprivation data (the Index of Multiple Deprivation) and Hospital Episode Statistics (HES) (Department for Communities and Local Government, 2011) . Practices with linked data have been shown to be similar to practices without linkage in respect of demographic data, years of follow-up and prescribing of medication (Gallagher et al., 2011) . All doctors in practices contributing to CPRD are trained in their recording of consultations and diagnostic codes, and CPRD has been validated in previous studies (Herrett et al., 2010 (Herrett et al., , 2015 .
Study participants
This study represents secondary data analysis of an established cohort (Bedson et al., 2016) . We identified women aged 18-55 years old from within the cohort, starting a long-term opioid (defined below) and with a coded noninflammatory potentially painful MSK condition from 2002 to 2012. The following factors were used as exclusion criteria: a cancer diagnosis at any time prior to the first day of opioid use or within the following 6 months and <1 year of records within CPRD prior to the first day of opioid prescription. MSK conditions were identified from the database using a previously defined list of Read codes (a clinical coded dictionary used for recording consultations in the UK primary care IT systems; list available online at www.keele.ac.uk/mrr) (Jordan et al., 2010; Health and Social Care Information Centre, 2015) . Opioids were defined as analgesics used to relieve moderate or severe pain and were identified from sections 4.7.1. and 4.7.2. of the British National Formulary (BNF) (Joint Formulary Committee, 2014) . This definition includes weak opioids such as codeine, and potent opioids such as morphine, both in long-acting (duration of action 12 h or longer) and short-acting (duration of action 4-6 h) forms (Fallon et al., 2006) . Long-term opioid use was defined as the issue of least three opioid prescriptions within 90 days from and including the first date of a new prescription for opioids. A new episode of opioid use starts on the date of an opioid prescription if there had been no opioids prescribed within the previous 6 months. This definition is in the line with the classification of long-term opioid use in previous studies, and the definition was developed by Von Korff et al. (2008) following exploratory analyses (Von Korff et al., 2008; Dunn et al., 2010; Bedson et al., 2016) . Any opioid prescription not fitting this definition at any point during 2002-2012 was defined as short-term opioid use (i.e. a maximum of two prescriptions within a 90-day period). The end of a period of opioid use was defined by a gap of more than 6 months from last use of opioids, which was taken to be 28 days after the issue of the last prescription (prescribing guidelines for controlled drugs from the NHS Business Services Authority state that no more than a 28-day supply should be given except in exceptional circumstances)(NHS Business Services Authority, 2014).
MSK conditions were identified from between 14 days before and 90 days after the start of a new episode of opioid use in order to create a temporal association between a new opioid prescription and an MSK condition. MSK conditions were chosen as they represent a large proportion of CNCP patients, with arthritis being identified as the cause for CNCP in 40% of UK patients. MSK conditions are a homogenous group and limit confounding by indication (Breivik et al., 2006) .
Study design
We conducted a matched cohort study consisting of women starting a long-term opioid (exposed population) at the time of an MSK condition, matched to women starting a short-term opioid (nonexposed population) at the time of an MSK condition. We matched for year of birth (up to AE5 years), general practice and first year of opioid use (up to AE2 years).
Follow-up
Follow-up started from 90 days after the initial opioid prescription (in both short-term and long-term opioid users) until the study outcome occurred, or for a maximum of 5 years. Censoring occurred if the patient no longer contributed data (death, practice leaving CPRD or patient leaving a CPRD practice) or if the study end date was reached (10th January 2012) prior to the end of the 5-year follow-up period.
Outcome measures
The primary outcomes of interest were defined following a systematic review by the authors. These were altered menstruation, amenorrhoea (absent menstruation) or oligomenorrhoea (less frequent menstruation, either less than nine menstrual periods a year or at least 35 days in between menstrual periods), decreased libido, menopause and infertility (The Practice Committee of the American Society for Reproductive Medicine, 2008; Impey and Child, 2012; Norwitz and Schorge, 2013; Wersocki et al., 2017) . These outcomes were identified through searching the database for relevant Read codes from 90 days after commencing opioids until end of follow-up. The Read code list for each outcome was developed by ER and then reviewed by JB who is experienced in developing Read code lists and a consensus decision was reached; both are academic GPs in the UK (lists available online at www.keele.ac.uk/ mrr). Outcomes were analysed separately so each participant could have more than one outcome.
Covariate data
Data on comorbidities were collected over a 15-month time period, from 12 months before initial opioid prescription until 3 months after (when follow-up began). Three types of comorbidity data were identified. The outcomes of interest were considered comorbidities if they occurred prior to the start of follow-up, and they were identified in the same way as described for outcome measures. The following covariates were also identified: thyroid conditions, low BMI <18 (as a coded condition), adrenal conditions and obesity (as a coded condition), and BMI (categorized as <25 kg/m 2 , ≥25 kg/m 2 (overweight) or missing) was recorded at the date closest to the start of follow-up, structural gynaecology condition and illegal opioid misuse. These conditions were chosen following a literature search for common conditions that could be associated with the outcomes of interest. Finally, the total number of prescriptions were mapped to BNF sections and used as a surrogate measure for the number of comorbid conditions (Perkins et al., 2004) .
Alcohol and smoking were categorized as never, ever or missing and were identified prior to the start of follow-up. Age was included within analysis as a continuous variable.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been associated with anovulation; therefore, we specifically identified coprescribing with NSAIDs for 4 months prior to the start of follow-up (Salman et al., 2015) .
Statistical analysis
The baseline demographics of the two groups were first described and compared using appropriate simple statistical tests (Wilcoxon-Mann-Whitney or chisquared test).
The rates of adverse events per 10,000 person-years at risk in short-term and long-term opioid user groups were determined. Cox proportional hazards models were used to produce both unadjusted and adjusted hazard ratios (HRs), estimating the effects of association between opioid use and reproductive dysfunction. The validity of the proportional hazards assumption was tested using Schoenfeld residuals; where the proportional hazards assumption was violated those covariates were included as time-varying covariates (see Table 1 ) (Bellera et al., 2010) . HRs were adjusted for the covariates described above. Sensitivity analyses were undertaken using first a complete case approach, secondly removing those with pre-existing outcome conditions and finally removing all those women with reported menopausal symptoms (a proxy for analysis of those not receiving hormone replacement therapy (HRT)). Data were analysed using STATA 14.0 (StataCorp, 2017).
Ethics committee approval
This study was approved by the CPRD Independent Scientific Advisory committee (reference number ISAC, Protocol No. 13_135).
Results
The study cohort included 44,260 women (22,130 long-term opioid users and 22,130 short-term users). Table 2 shows the baseline characteristics of the two groups. The median age in both groups was 43. Long-term opioid users were more likely to use NSAIDs, have a higher BMI, have more comorbidities and to be smokers when compared with shortterm opioid users (see Table 2 ). Median follow-up was 39 months; the total number of years under follow-up for each outcome is shown in Table 3 .
The incidence in abnormal menstruation was higher for long-term opioid users (209.5 per 10,000 person-years (95% CI 199.0-220.7)) than for shortterm opioid users (186.2 per 10,000 person-years (95% CI 176.4-196.7)). The adjusted HR showed an increased risk of abnormal menstruation 1.13 (95% CI 1.05-1.21) for long-term opioid users compared with short-term opioid users over the 5-year followup. The incidence of menopausal symptoms was higher in long-term opioid users (383.7 per 10,000 person-years (95% CI 369.1-398.8)) than in shortterm opioid users (330.9 (95% CI 317.5-344.8)). The adjusted HR was 1.16 (95% CI 1.10-1.23) for long-term users compared with short-term users.
Low libido had an incidence of 27.7 per 10,000 person-years (95% CI 24.0-31.8) in long-term opioid users and of 22.6 (95% CI 19.4-26.4) in short-term opioid users. The adjusted hazard ratio did not find a statistically significant difference in risk of low libido between long-term and short-term opioid users (adjusted HR 1.19, 95% CI 0.96-1.48).
Infertility had an incidence in short-term opioid users of 19.0 per 10,000 person-years (95% CI 16.0-22.5) and a lower incidence in long-term opioid users of 16.4 (95% CI 13.7-19.7). However, there was no statistically significant difference in risk of infertility seen with the adjusted Cox regression between short-term and long-term opioid users (adjusted HR 0.82, 95% CI 0.64-1.06).
Sensitivity analysis using only complete cases, removing those with menopausal symptoms and also for those without pre-existing reproductive dysfunction gave similar results (see Table 4 ).
Discussion
To our knowledge, this study of over 40,000 opioid users in primary care is the first to demonstrate an increased risk of abnormal menstruation and of menopausal symptoms in women aged 18-55 years prescribed long-term opioids compared with shortterm opioids. The relationship between opioid use and low libido and infertility was not so clear. These results are consistent with the limited current literature, where a recent systematic review found a possible relationship between opioid use and female reproductive dysfunction (Wersocki et al., 2017) .
Women aged 18-55 years old with painful MSK conditions and prescribed opioids were identified for this study. We used MSK pain to define the cohort rather than all-cause CNCP as MSK conditions represent a large proportion of CNCP cases and are a more homogenous group of conditions, in order to address some elements of indication bias (Breivik et al., 2006) . However, residual confounding cannot be ruled out as one explanation for the findings, particularly where severity and longevity of the MSK condition are not taken into account. We also cannot be completely confident that the opioid was prescribed for an MSK condition, as if the indication was a different type of pain, this may introduce additional confounding. As our cohort included only participants with MSK pain, this may mean the results are not generalizable to other types of CNCP. It is also important to note that the MSK conditions include all joints and all MSK conditions that would not be considered inflammatory. Accordingly, this still represents a broad group of conditions. The women in the long-term opioid use group also had a higher number of comorbidities than the short-term opioid use group which could indicate that they may experience poorer health in general. Additionally, the increased stress levels that may be associated with increased comorbidity can be associated with some of the outcomes of interest; however, this was adjusted for during Cox regression (The Practice Committee of the American Society for Reproductive Medicine, 2008). Long-term opioid users were also more likely to be smokers, and there is some evidence that smoking can be associated with premature ovarian failure (POF). However, we were able to include smoking within the analysis in order to account for this (Luborsky et al., 2003) .
There was a significant difference seen for alcohol use as well, with long-term opioid users appearing to drink less alcohol. There is evidence that alcohol use can be associated with low libido and this was also adjusted for within the analysis (Arunakumari and Walker, 2009 ). The groups were also significantly different in statistical terms with respect to ethnicity where there was also a large amount of missing data. As a consequence, we were unable to adjust for ethnicity and this is a potential limitation as there is some evidence that distinct ethnic groups enter the menopause at different ages and experience variation in rates of POF (Luborsky et al., 2003) . Everyone in the cohort was considered suitable to receive prescribed opioids, and this decreases potential systematic differences between the comparison groups. However, the groups may still be different in terms of the severity or nature of the underlying condition. We have also not assessed the impact of daily morphine equivalent opioid dose, and it may be that long-term users were receiving higher daily doses, although there is evidence in the UK that the majority of long-term opioid users are receiving less potent opioids such as codeine 15 mg; this would be an important area for future research (Bedson et al., 2016) . The identification of women as either longterm or short-term opioid users was based on issued prescriptions, although we cannot definitely establish how or if the patient used the medication. It is also important to note that opioid exposure was only identified at baseline and participants did not move in and out of opioid exposure groups, whereas in real life, opioid exposure is time varying so this may have an impact on the generalizability of the results.
The study is unable to report on the risk associated with opioid use compared with no opioid use for the adverse effects studied (as the comparison was between opioid duration), which is a limitation of the study. However, it was felt that comparing duration of opioid use reduced the likelihood of confounding by indication and this was an important consideration when designing the study. It also removed the possibility of contraindications to opioid prescribing affecting the prescription of opioids in either group. Further attempts were made to control for confounding through statistical adjustment for important factors including: age, BMI, NSAID use and medical conditions associated with the outcomes of interest. The study did not identify women receiving HRT or hormonal contraception, and these may have affected results, but there is no reason to suspect usage is different between the short-term and long-term opioid users. We undertook a sensitivity analysis where women with a diagnosis of menopause were removed and there was no difference seen in the results for the other outcomes (see Table 4 ). We were unable to include hormonal contraception within the analysis as CPRD does not capture all the relevant information. In the period from April 2012 to March 2013, 1.2 million women in the UK attended family planning clinics and of these 47% received oral contraception and this information would not be routinely recorded within CPRD (Health and Social Care Information Centre, 2013) . Given the different routes through which women can access oral contraception, we were unable to confidently include this within the analysis.
The use of CPRD was a strength, as it allowed us access to a large sample of opioid users which provided enough statistical power to undertake the appropriate analysis. A particular strength of this study when compared to the current body of evidence which is mainly set in secondary care is its generalizability to primary care, as CPRD is broadly representative of the UK population (Herrett et al., 2010) . Only 23% of pain patients are seen by a pain specialist, so these secondary care studies may represent a subset of patients with more severe pain conditions (Breivik et al., 2006 ). There will be little missing data, as in the UK prescriptions are recorded automatically in the electronic records on issue and CPRD practices must code a condition when prescribing; this will also have helped reduce missing data when identifying outcomes of interest (Lawson et al., 1998) . In the UK, the only opioids available without a prescription are low dose codeine and dihydrocodeine and then they are only recommended for a maximum of 3 days for acute painful injuries, and come in a maximum pack size of 32 tablets, so any long-term opioid use should be via prescription (Medicines and Healthcare products Regulatory Agency, 2009). CPRD has previously been shown to be valid for identifying patients with MSK conditions (Jordan et al., 2006) . A review of CPRD studies found a median proportion of confirmed diagnoses of 89% over 357 validation studies examining 183 diagnoses (Herrett et al., 2010) . The number of women with low libido within the cohort was lower than would be expected, with only 0.8% of the cohort having a coded diagnosis compared with population estimates of between 25% and 50% (Dunn et al., 1998; Laumann et al., 2005) . This is likely to have affected the possibility of finding a statistically significant relationship. This also raises the question as to why there were such low numbers. Sexual dysfunction is a more subjective condition in women when compared to men and they may worry about their privacy in relation to presenting clinically (Montgomery, 2008) . Treatment options for sexual dysfunction in women are poor. Consequently, women with sexual dysfunction infrequently present in primary care creating a clinical iceberg (Last, 1963) . Investigation of low libido might be better undertaken in other ways, for instance a cross-sectional study.
In conclusion, this large cohort study has uniquely found that women aged 18-55 years receiving longterm opioids for painful MSK conditions were at increased risk of menopause and abnormal menstruation when compared with women receiving shortterm opioids. This is an important finding against the background of increasing long-term opioid use (Bedson et al., 2016) . This should be considered when clinicians are prescribing opioids and discussed with patients. If a patient is receiving opioids, this should be considered when investigating women presenting with reproductive dysfunction. It is recommended that clinicians undertake regular reviews of patients prescribed long-term opioids and to assess the effectiveness of the medication but also to raise the possibility of adverse effects including reproductive adverse effects as patients may not volunteer these symptoms. The study was unable to find a definite link for low libido, and further research is required, potentially using direct patient data collection. Further research may also be needed to identify whether there is a daily dosage level where risk becomes more significant.
